Cysteine modified antibody-drug conjugate and preparation method thereof

Inventors

Zhu, Yi • WANG, YIXI • Zhuo, Shi • Li, Jie • Chen, Lan • WAN, Weili • YU, Yongguo

Assignees

Systimmune Inc

Interested in licensing this patent?

MTEC can help explore whether this patent might be available for licensing for your application.

Publication Number

US-11484605-B2

Patent

Publication Date

2022-11-01

Expiration Date


Abstract

By inserting cysteine (C) into a heavy chain and/or a light chain of a target antibody at specific insertion site, and performing a site-specific conjugation through a free thiol group (—SH) from the site-specific inserted cysteine and a linker conjugated with a highly potent small molecule cytotoxin, a cysteine modified antibody-drug conjugate with good homogeneity is provided. The specific insertion sites of cysteine are position 205 and/or position 206 (Kabat numbering scheme) of the light chain of the antibody, and/or position 439 (Kabat numbering scheme) of the heavy chain.

Core Innovation

The invention is directed to a cysteine modified antibody-cytotoxin conjugate comprising an antibody and a cytotoxin. The antibody comprises an inserted cysteine at a cysteine insertion site so that the antibody comprises a light chain amino acid sequence GLSSPCVTKSF (SEQ ID NO: 13), or a light chain amino acid sequence GLSSPVCTKSF (SEQ ID NO: 14), or a heavy chain amino acid sequence TQKSLSCLSPGK (SEQ ID NO: 15). The inserted cysteine contains a thiol group, and the cytotoxin is conjugated to the thiol group through a linker.

Cytotoxin payloads are conjugated to the thiol group via a linker, including MMAE, MMAF, PBD, SN-38, Dox, and derivatives. The constructs retain antigen affinity, because the cysteine insertion is defined by specific Kabat positions and corresponding amino acid sequence embodiments (SEQ ID NO: 13-15). Conjugates are formed between an antibody carrying an inserted cysteine thiol and a cytotoxin moiety connected through a linker.

A conjugate preparation workflow is described that uses antibody reduction to generate the free thiol associated with the inserted cysteine, followed by conjugation to a linker-drug payload containing a cytotoxin moiety, and removal of unconjugated payload. The workflow also includes oxidizing the reduced antibody to restore inter-chain disulfide bonds. Purification is described using cation exchange chromatography and ultrafiltration, with examples of conjugated payloads including mc-vc-PABOH and mc-vc-PAB-payloads such as mc-vc-PAB-MMAE, mc-vc-PAB-MMAF, mc-vc-PBD, mc-vc-PAB-DOX, and mc-vc-PAB-SN-38.

Claims Coverage

The independent claim covers a cysteine modified antibody-cytotoxin conjugate with an antibody containing a thiol-bearing inserted cysteine defined by specific light-chain or heavy-chain amino acid sequences (SEQ ID NO: 13-15), and a cytotoxin conjugated to that thiol through a linker. Dependent claims narrow and specify which chain sequence is used, specify example cytotoxin payloads, constrain a cytotoxin-to-antibody ratio, and recite a conjugate preparation workflow and purification operations.

Inserted cysteine thiol-containing antibody with specified light-chain or heavy-chain sequences

An antibody comprising an inserted cysteine at a cysteine insertion site such that the antibody comprises a light chain comprising GLSSPCVTKSF (SEQ ID NO: 13), or a light chain comprising GLSSPVCTKSF (SEQ ID NO: 14), or a heavy chain comprising TQKSLSCLSPGK (SEQ ID NO: 15), wherein the inserted cysteine comprises a thiol group.

Cytotoxin conjugated to the inserted cysteine thiol through a linker

A cytotoxin conjugated to the thiol group through a linker, forming a cysteine modified antibody-cytotoxin conjugate.

Specified cytotoxin payload set

The cytotoxin is selected from MMAE, MMAF, PBD, SN-38, Dox, or a derivative thereof.

Conjugate preparation with reduction, unshielding, oxidation, conjugation, and purification

A method preparing a cysteine-modified antibody-cytotoxin conjugate by reducing an antibody to unshield an inserted cysteine thiol, removing decoupled shielding group and reducing agent via cation exchange chromatography or ultrafiltration, oxidizing to restore inter-chain disulfide bonds, conjugating an mc-vc-PAB-payload containing a cytotoxin moiety to the free thiol, and removing unconjugated mc-vc-PAB-payload via cation exchange chromatography or ultrafiltration.

Cytotoxin-to-antibody ratio range of 1.6 to 2

The cytotoxin-to-antibody ratio is 1.6 to 2.

Overall, the claim set focuses on conjugation chemistry driven by an inserted cysteine thiol in a specifically defined antibody light-chain or heavy-chain sequence (SEQ ID NO: 13-15), coupled with cytotoxin/linker conjugation, optional restriction to named cytotoxins, an explicit cytotoxin-to-antibody ratio range, and a described workflow that includes reduction, unshielding, oxidation to restore inter-chain disulfide bonds, thiol-linker-drug conjugation, and purification steps.

Stated Advantages

Retention of antigen affinity is noted.

Documented Applications

No documented applications found

JOIN OUR MAILING LIST

Stay Connected with MTEC

Keep up with active and upcoming solicitations, MTEC news and other valuable information.